Conclusion
The recognition of NTRK as a potential oncogene is now dated, the proper understanding of the specific mechanisms involved and their appreciation as a potential therapeutic target is far more recent. NTRK inhibitors have shown high efficacy in multiple NTRK-driven cancers shining the concept of ”targeted therapy”.
This case illustrates the response seen in pediatric intramedullary spinal cord LGGs with NTKA2 fusion treated with Larotrectinib. This case’s findings are similar to the findings of a clinical trial that was conducted for 24 patients, highlighting the potential of targeted therapies in pediatric patients when oncogenic drivers can be identified and selective inhibitors are available. Accordingly, our case suggests the use of the multi-layer diagnosis integrating histopathology and molecular genetics analysis could have significant prognostic implications.